Background: Rheolytic thrombectomy (RT) for acute iliofemoral deep vein thrombosis (DVT) with fi rst-generation techniques is often incomplete and adjunctive conventional catheter-directed thrombolysis (CDT) is required in more than half of patients to achieve venous patency. Patients and methods: From the prospective Bern Venous Stent Registry, we investigated rates of primary treatment success, primary patency, and post-thrombotic syndrome (PTS) from 40 consecutive patients (mean age 51 ± 19 years, 45 % women) with acute iliofemoral DVT, treated with a novel directional RT technology and stent placement. Overall, 24 patients were treated for native-vessel iliofemoral DVT (11 with single-session RT, 13 with bailout RT after failed CDT) and 16 for iliofemoral stent thrombosis. Pulse-spray thrombolysis (r-tPA 10 mg) was performed in 29 (73 %) patients. The mean follow-up duration was 193 ± 132 days (minimum 90 days). Results: Overall, primary treatment success of RT was 95 %; only two patients required adjunctive CDT to restore patency. In 24 patients with native-vessel DVT, six-month primary patency was 92 % (95 %CI 75-99 %), and 23 patients (96 %) were free from the PTS according to the Villalta score. In 16 patients with stent thrombosis, six-month primary patency was 63 % (95 %CI 35-85 %) and 50 % were free from PTS. Except for transient macroscopic haemoglobinuria in all patients, no other side effects were recorded. Conclusions: In patients with iliofemoral DVT of native or stented vessels, RT followed by stent placement appears to be effective and safe. The novel technique enables single-session DVT treatment in the majority of patients without the need for prolonged CDT.
Introduction
Acute iliofemoral deep vein thrombosis (DVT) is a major cause for morbidity, as approximately half of the patients managed conservatively with anticoagulation therapy and compression stockings develop the post-thrombotic syndrome (PTS) [1] [2] [3] [4] . The residual thrombus load correlates with the probability of a future PTS [5, 6] . The degree of the PTS correlates with impairment of quality of life [7, 8] .
As compared to conservative therapy, catheter-directed thrombolysis (CDT) is associated with greater venous patency and reduced risk of PTS at two years [9] . International consensus guidelines recommend CDT with provisional stent placement of the underlying venous outfl ow obstruction for selected patients with acute iliofemoral DVT [10, 11] . However, CDT with provisional stent placement is complex because it involves catheter placement http://econtent.hogrefe.com/doi/pdf/10.1024/0301-1526/a000666 -Friday, April 06, 2018 2:35:00 AM -University of Bern IP Address:130.92. 15.44 patients required adjunctive CDT to restore venous patency. The Angiojet ZelanteDVT® catheter (Boston Scientifi c, Maple Grove, MN, USA) is a novel 8-French RT system specifi cally designed for single-session treatment of acute iliofemoral DVT.
The aim of the present study was to investigate patency rates and early clinical outcomes of patients with acute iliofemoral DVT treated with the Angiojet ZelanteDVT® system.
Patients and methods

Study design
The current analysis was derived from the Bern Venous Stent Registry, an ongoing study that consecutively enrols patients who received venous stents at the University Clinic of Angiology in Bern, Switzerland, since 1 January 2008. From this registry we included all patients with least 90 days of follow-up, who underwent AngioJet ZelanteDVT® for acute iliofemoral DVT or iliofemoral venous stent thrombosis since market introduction in December 2015. Exclusion criteria for registry enrolment are the inability to provide informed consent, age below 18 years, or estimated life expectancy < 3 months.
The registry and participant consent form were approved by the Swiss Ethics Committee on research involving humans. The study is registered on the National Institutes of Health website (ClinicalTrials.gov; identifi er NCT02433054).
For all enrolled patients, baseline demographic information (age, gender, weight, height, indication), comorbid conditions (concomitant pulmonary embolism, active cancer or treatment, thrombophilia, hypertension), risk factors (smoking, hormonal therapy, previous DVT, immobility, recent surgery/trauma, May-Thurner compression, obesity), and anticoagulant/antiplatelet therapy were recorded. Procedural data included type, diameter, length, and site of implanted stents. Venograms were used to analyse thrombus extension and primary treatment success.
For this analysis we predefi ned three patient groups: 1. primary single-session RT for iliofemoral DVT of native vessels, 2. bail-out RT after incomplete or failed CDT for iliofemoral DVT of native vessels, 3. primary single-session RT of DVT caused by iliofemoral venous stent thrombosis.
Study device
The Angiojet ZelanteDVT ® (Boston Scientifi c, Marlborough, MA, USA) catheter is a novel RT device which has been specially designed for single-session treatment of iliofemoral DVT (Figure 1 ).
Procedures
Iliofemoral DVT was objectively confi rmed by duplex ultrasound or contrast-enhanced computed tomography. All patients were initially treated with intravenous unfractionated heparin, adjusted to target and partial thromboplastin time corresponding to therapeutic heparin levels was activated (equivalent to 0.3 to 0.7 U/mL by factor Xa inhibition). In patients with thrombus extension into the popliteal veins, initial CDT was mainly performed as a fi rst thrombus removal strategy. Following popliteal access with a 10-French sheath, RT (AngioJet ZelanteDVT ® ) was performed using two thrombectomy passes of the thrombotic occlusion by advancing the device by 2-3 millimetre per second. Each device activation run lasted no longer than 30 seconds with breaks of 30 seconds in between the runs to avoid arrhythmia. During the thrombectomy procedure, the rotation hub at the catheter shaft was rotated by 270 degrees back and forth to accomplish circumferential thrombus removal. If RT was incomplete, defi ned as absence of fl ow or residual thrombus with near complete vessel occlusion, an intraclot injection of 10 mg of r-tPA (total injected volume 30 millilitres) using the PowerPulse® technique was performed. After 20 Minutes dwell time, another two thrombectomy passes were performed as described above, not exceeding a total device activation time of 300 seconds. Diagnosis of an iliac vein compression syndrome or of residual post-thrombotic obstruction was established after successful thrombus removal by digital subtraction venography in two orthogonal views or by intravascular ultrasound if venography was equivocal. Stenting was performed in the presence of a venous stenosis > 50 % by intravascular ultrasound or venography or in the presence of collateral fl ow, or in the absence of fl ow [14] .
Depending on the aff ected venous segment and the presence or absence of a compression syndrome, the following stents were used: for the inferior vena cava Sinus-XL® stent, for compressed iliac veins Sinus-Obliquus® May Thurner stent, for post-thrombotic iliac or common femo- It is an isovolumetric, directional, hydrodynamic thrombectomy device using accelerated reversed fl uid, which runs through the inside of the catheter and provides a strong -600 mmHg suction (Venturi) effect at the catheter tip. The treatment segment with one larger proximal suction window and one smaller distal outfl ow window (arrows) can be identifi ed under fl uoroscopy through two marker bands. Between the marker bands is an eccentric middle marker, indicating the (opposite) direction of the infl ow and outfl ow windows. 
Clinical follow-up
Clinical follow-up assessments with duplex sonography were performed in all patients at the vascular outpatient clinic by vascular specialists at the fi rst postinterventional day, at three, six, and 12 months. At each visit, signs and symptoms of post-thrombotic syndrome, including all points of the Villalta score [15] and the revised venous clinical severity score [16] were systematically examined by vascular specialists. Each stented venous segment was examined by ultrasound for (1) the presence or absence of thrombotic changes (thickening of the venous wall, intraluminal webs, intraluminal material) and (2) fl ow patterns in treated segments to determine if they were modulated by the cardiac cycle, spontaneously modulated with respiration, or modulated with deep inspiration. Peak fl ow velocities [cm/sec] were recorded from the common femoral vein.
Defi nition of outcomes
Primary treatment success was defi ned as antegrade fl ow and maximal luminal stenosis of 30 % assessed on the final procedural venography and evidence of a spontaneous Doppler signal in the treated vein segment [17] . Primary patency rate was defi ned as the percentage of patients with primary treatment success and without the occurrence of either thrombosis of the treated segment or a reintervention to maintain patency of the treated segment. Restenosis in the treated venous segment was defi ned by ultrasound as a luminal obstruction of > 50 % of the venous cross-sectional area in B-mode or deterioration of the Doppler fl ow pattern from the fi rst postinterventional day to the follow-up ultrasound study. This included an increase of the peak fl ow velocity to > 1 m/s or a loss of respiratory modulation of fl ow.
Statistical analyses
Continuous baseline and outcome data were presented as mean ± standard deviations and were compared between the three groups, using one-way analysis of variance and Dunn's multiple comparison tests. Categorical baseline and outcome data were analysed between the groups using the chi-square test. Kaplan-Meier survival analysis was used to estimate patency rates, which were reported with the 95 % confi dence interval. A log rank test was used to compare primary patency rates between patients with iliofemoral DVT and patients with iliofemoral venous stent thrombosis. A p < 0.05 indicated statistical signifi cance. For data management and statistical analysis, we used the Prism® V5.0f statistical software package (GraphPad®, San Diego, CA, USA).
Results
Baseline characteristics
Overall, 40 patients (mean age 51 ± 19 years; 18 women) were treated with directional RT between December 2015 and March 2017. During the observation period, fi ve patients with iliofemoral DVT were treated conservatively. Baseline characteristics were similar in the groups except for a history of previous DVT and hormonal therapy (Table I) . Overall, 24 patients (60 %) had acute iliofemoral DVT of native veins of which 11 were treated in a single session and 13 in a bail-out session after incomplete CDT with r-tPA 20 mg over 15 hours. Sixteen patients (40 %) presented with iliofemoral venous stent thrombosis; the index diagnosis and reason for stent implantation was PTS in 11 cases (69 %) and acute iliofemoral DVT in fi ve cases (31 %). Figure 2 shows an example of venograms at baseline, after RT, and at completion of the procedure for the three groups. Primary treatment success after RT was achieved in 38 patients (95 %). In two patients, adjunctive CDT was necessary to achieve venous patency. None of the 40 patients received an IVC fi lter. Balloon angioplasty and stent placement was performed in all patients (mean 3.5 ± 3.2 stents) (Table II) . Among the 16 patients with stent thrombosis, 15 (94 %) patients had post-thrombotic venographic changes of the leg infl ow veins (femoral and deep femoral veins) at the time of the index procedure.
Procedural data
There were no periprocedural adverse events, such as arrhythmia, bleeding complications or symptomatic pulmonary embolism. Transient macroscopic haemoglobinuria during the fi rst 24 hours after intervention was recorded in all patients. The majority of patients received oral anticoagulation therapy with either direct oral anticoagulants 
Clinical outcome during follow-up
The mean follow-up duration was 193 ± 132 days (Table II) . For the 24 patients with iliofemoral DVT of native vessels, the primary patency rate was 92 % [95 % CI 75-99 %] at 180 days ( Figure 3 ). There was one female patient with metastatic bladder cancer who had right-sided iliac stent thrombosis at day 165, due to tumour progression with compression of the inferior vena cava and iliac veins. She underwent successful stent reconstruction of the inferior vena cava and iliac veins.
For the 16 patients with stent thrombosis, the primary patency rate was 63 % [95 % CI 35-85 %] at 180 days ( Figure  3 ). Six patients with an index diagnosis of PTS had symptomatic complete stent rethrombosis, of whom two had early rethrombosis within 30 days. Among the six patients, reintervention was attempted in three, but not successfully.
Among the seven patients who developed symptomatic stent thrombosis at follow up, six (86 %) had post-thrombotic venographic changes of the femoral leg infl ow veins at the index procedure. Among the 33 patients with patent stents at the latest follow-up, only nine (27 %) had post-thrombotic venographic changes of the femoral leg infl ow veins at the index procedure (p = < 0.001). Among the 40 patients, there were no cases of asymptomatic venous restenosis. Overall, the Villalta score at six months was 3.87 ± 5.04; 30 patients (75 %) were free from PTS with a Villalta score of < 5 points (Table II) . Among the 24 patients with iliofemoral DVT, 23 (96 %) remained free from the PTS at six months with a Villalta score of < 5 points. Among the 16 patients with venous stent thrombosis, seven (44 %) were free from PTS at six months.
Discussion
We report the fi rst early clinical results of a novel directional RT technique for the treatment of iliofemoral DVT. Directional RT using the AngioJet ZelanteDVT® system was eff ective to restore patency in combination with balloon angioplasty and venous stent placement in patients with iliofemoral DVT of native or stented vessels. PowerPuls® thrombolysis was performed in 73 % patients and only 5 % required adjunctive CDT to achieve venous patency. Except for transient haemoglobinuria, no periprocedural complications occurred.
In the 24 patients with acute iliofemoral DVT of native vessels, six-month primary patency was 92 % and only one patient developed PTS. In patients with iliofemoral venous stent thrombosis, six-month primary patency was 63 %, and 56 % of the patients remained free from PTS. The main reason for the less favourable patency rate in patients with iliofemoral venous stent thrombosis was likely an impaired venous stent infl ow because almost all patients had post-thrombotic femoral veins at the index procedure. Despite lower patency rates, interventions for venous stent thrombosis should be considered because a permanently obstructed deep venous system may be associated with impaired quality of life and invalidity, leading to substantial disease-related costs [18, 19] .
The novel directional RT technique was specifi cally designed for thrombus removal in large veins. In contrast to fi rst-generation RT systems, features of the novel technique include (1) a larger catheter lumen (8F instead of 6F), (2) modifi cations at the treatment segment with one larger proximal suction window and one smaller distal outfl ow window, and (3) a rotational hub to accomplish directional thrombus removal (see Figure 1) . The novel RT technique provides a strong -600 mmHg suction (Venturi-) eff ect at the catheter tip which is likely the reason for the observed primary treatment success without the need for adjunctive prolonged CDT in all but two patients. This clearly is an improvement when comparing our results to the results of the PEARL study, in which 61 % of the patients treated by the fi rst-generation RT technique required adjunctive CDT to restore venous patency [13] .
There is an ongoing debate whether an early revascularization strategy is superior to anticoagulation therapy exclusively for the reduction of PTS in patients with acute iliofemoral DVT [20] . First results from the Acute venous Thrombosis: Thrombus Removal with Adjunctive Catheter-directed Thrombolysis randomized (AT-TRACT) trial [21] , which compared an early revascularization strategy to just anticoagulation therapy in 692 patients with proximal DVT, were presented at the congress of the Society of Interventional Radiology (SIR) in March 2017 [22] . Unfortunately, almost half of the ATTRACT patients had femoropopliteal DVT without involvement of the iliac veins; several thrombus removal strategies were allowed and only 30 % of the patients had stent placement. The ATTRACT study failed to show that an early revascularization strategy was superior to just anticoagulation with similar overall PTS rates at two years of follow-up.
Currently, there is no evidence from randomized trials that RT is more eff ective than conventional CDT. It re- a: Continuous data are presented as the mean ± standard deviation, categorical data are given as numbers with percentages; b: at last follow-up; c: revised venous clinical severity score at last follow-up; d: for the initial three months after intervention; e: by Doppler ultrasound in the common femoral vein after completion of the procedure; PTS: post-thrombotic syndrome. 
Limitations and conclusions
Our study is limited by the relatively low number of study participants and short follow-ups. Nevertheless, our fi rst clinical results suggest that primary treatment success and early clinical outcomes with this novel RT technique are favourable for patients with iliofemoral DVT. Overall, RT was eff ective to restore patency in combination with provisional PowerPuls® thrombolysis, balloon angioplasty, and venous stent placement. The novel technique enables single-session DVT treatment in the majority of patients without the need for prolonged catheter-directed thrombolysis. Future studies should investigate the long-term effi cacy and safety of this promising technique in large cohorts of patients with acute iliofemoral DVT.
